XM does not provide services to residents of the United States of America.
G
G

Gilead

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

FDA Expands Indication For Gilead's Vemlidy To Treat Chronic HBV Infection In Pediatric Patients As Young As Six

BRIEF-FDA Expands Indication For Gilead's Vemlidy To Treat Chronic HBV Infection In Pediatric Patients As Young As Six March 28 (Reuters) - Gilead Sciences Inc GILD.O : FDA EXPANDS INDICATION FOR GILEAD'S VEMLIDY (TENOFOVIR ALAFENAMIDE) TO TREAT CHRONIC HBV INFECTION IN PEDIATRIC PATIENTS AS YOUNG AS SIX GILEAD - EFFICACY AND SAFETY PROFILE OF ONCE
G

Xilio Therapeutics surges on license deal with Gilead, job cuts

BUZZ-Xilio Therapeutics surges on license deal with Gilead, job cuts ** Drug developer Xilio Therapeutics's XLO.O shares more than triple to $2.04 premarket ** Co announces exclusive license agreement with Gilead GILD.O to develop and commercialize its cancer therapy ** Under the terms of the deal, XLO will receive $43.5 mln upfront and will also b
G

Gilead And Xilio Announce Exclusive License Agreement For Tumor-Activated Il-12 Program

BRIEF-Gilead And Xilio Announce Exclusive License Agreement For Tumor-Activated Il-12 Program March 28 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD AND XILIO ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR TUMOR-ACTIVATED IL-12 PROGRAM GILEAD AND XILIO ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR TUMOR-ACTIVATED IL-12 PROGRAM XILIO WILL RECEIVE $43.5 MILLION IN UPFRONT PAYMENTS XTX301 IS CURRENTLY BEING EVALUATED IN A PHASE 1 DOSE ESCALATION TRIAL IN PATIENTS WITH ADVANCED SOLID TUMORS.
G

Gilead Says CEO Daniel O’Day's 2023 Total Compensation Was $22.6 Mln Versus $21.6 Mln In 2022

BRIEF-Gilead Says CEO Daniel O’Day's 2023 Total Compensation Was $22.6 Mln Versus $21.6 Mln In 2022 March 18 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD SAYS CEO DANIEL O’DAY'S 2023 TOTAL COMPENSATION WAS $22.6 MILLION VERSUS $21.6 MILLION IN 2022 - SEC FILING GILEAD SAYS CEO PAY RATIO FOR 2023 IS 110 TO 1 Source text for Eikon: [ID:n000130
G

Gilead T cancer therapy capacity to quadruple by 2026

Gilead CAR-T cancer therapy capacity to quadruple by 2026 By Michael Erman FREDERICK, Maryland, March 15 (Reuters) - Gilead Sciences GILD.O will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech's manufacturing processes, an executive in charge of that business told Reuters. Cindy Perettie, executive vice president of Gilead's Kite cell therapy unit, said these changes have already allowed the company to increase the number of p
G
N

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.